Bactiguard Holding AB AI Stock Analysis
Want to see SE:BACTI.B full AI Analyst Report?
Bactiguard Holding AB (BACTI.B) AI Stock Analysis
Bactiguard Holding AB
(Nasdaq OMX AB:BACTI.B)
Bactiguard scores below average, weighed down primarily by fundamentals that remain in transition: five years of flat revenue, still-negative operating income and a negative P/E of -64.6 show the business has yet to prove it can grow or sustain profitability, even as EBITDA has swung from a SEK -90m loss in 2023 to about SEK +49m TTM and free cash flow has turned positive. The balance sheet is a genuine strength — leverage reduced to roughly 0.52 debt-to-equity with equity funding about 60% of assets — but the capital base has shrunk materially through accumulated losses, leaving limited room for further missteps. Technicals add no support, with the price below all major moving averages and a negative MACD indicating a persistent downward drift, while the absence of a dividend means no income cushion. The investment case rests on management converting recent cost and cash-flow gains into sustained revenue growth; until that is evident, execution risk keeps the score muted. Weights applied: Financial Performance 50%, Technical Analysis 30%, Valuation 20%, with earnings call and corporate events excluded for lack of data and their weight redistributed.
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 520.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,890
- Price to Earnings (P/E)
- 82.5
- Beta (1Y)
- 0.30
- Revenue Growth
- -0.51%
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 166
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs)...
How the Company Makes Money
Bactiguard makes money primarily through (1) licensing its infection-prevention coating technology to medical device manufacturers and (2) selling coated medical devices in certain product categories/markets, depending on how products are commerciali...
Bactiguard Holding AB Financial Statement Overview
Summary
A turnaround in progress, but not yet complete. The income statement is the weakest link (score 41): revenue has been flat-to-choppy for five years at roughly SEK 170–244m (about SEK 215m TTM, down 11% in 2025 after +19% in 2024), EBIT remains marginally negative at about SEK -2m TTM, and the reported gross margin step-down from the 77–86% range to about 42% clouds visibility on unit economics. The balance sheet is the strongest pillar (score 60): debt has been cut from about SEK 248m in 2021 to SEK 154m, debt-to-equity has improved to roughly 0.52, and equity of about SEK 313m funds around 60% of assets — though the equity base has shrunk sharply from SEK 541m in 2021 on accumulated losses. Cash flow (score 55) has turned positive with about SEK 30m operating and SEK 28m free cash flow TTM on light capex, but it has flipped between positive and negative in four of the last five years, so consistency is unproven. Net: real cost and cash discipline progress, offset by absent revenue growth and lingering execution risk.
Income Statement
41NeutralBalance Sheet
60NeutralCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 214.73M | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 145.46M | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 48.72M | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | 6.02M | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | ||||||
| Total Assets | 524.24M | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 55.05M | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 153.75M | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 210.91M | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 313.33M | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | ||||||
| Free Cash Flow | 27.59M | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | 30.38M | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -2.79M | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -13.31M | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Negative. The current price of 14.85 is below the 20-day moving average (MA) of 15.51, below the 50-day MA of 15.63, and below the 200-day MA of 16.10, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 61.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
Overall Rating
SE:GETI.B67Neutral
SE:SEZI55Neutral
SE:BACTI.B47Neutral
SE:INTEG.B45Neutral
SE:OSSD45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | SEK 75.39B | 26.64 | 9.13% | 1.72% | -3.90% | 37.73% | |
| 55Neutral | SEK 510.16M | -5.23 | -35.44% | ― | 18.56% | 28.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | SEK 520.40M | 82.50 | 1.93% | ― | -0.51% | ― | |
| 45Neutral | SEK 238.78M | -5.66 | -20.71% | ― | 1.43% | 4.98% | |
| 45Neutral | SEK 329.67M | -6.59 | ― | ― | -11.89% | -11.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BACTI.B | Bactiguard Holding AB | 14.85 | -1.50 | -9.17% | |
| SE:GETI.B | Getinge AB (UK) | 276.80 | 71.25 | 34.66% | |
| SE:SEZI | Senzime AB | 3.25 | -1.81 | -35.87% | |
| SE:INTEG.B | Integrum AB Class B | 8.14 | -0.79 | -8.85% | |
| SE:PRO | Promimic AB | 9.00 | -8.05 | -47.21% | |
| SE:OSSD | OssDsign AB | 2.98 | -7.42 | -71.35% |
Bactiguard Holding AB Corporate Events
Bactiguard’s Partnership-Driven Growth Delivers Strong Q3 Turnaround
Bactiguard Holding AB reported a strong third quarter 2026, with total revenue rising 20.6% to SEK 58.4 million and net sales up 21.2% to SEK 55.1 million, driven mainly by its partnership model. Operating profit swung to SEK 6.8 million from a loss...
Bactiguard Sets Date for Q3 2026 Report and Investor Audiocast
Bactiguard Holding AB will publish its interim report for the third quarter of 2026 on 22 October at 07:00 CEST. The MedTech firm is organizing an audiocast and conference call the same day at 11:00 CEST, where CEO Christine Lind and CFO Patrick Bach...
Bactiguard Data Highlight Durable, Low-Silver Coating for Orthopedic Implants
Bactiguard has unveiled new data on its noble metal coating technology, reinforcing its distinct and durable performance on orthopedic implants. Presented at major international arthroplasty and infection conferences, the findings position the compan...
Bactiguard Adjusts Share Structure to Support 2026 Incentive Plan
Bactiguard Holding AB, a Stockholm-based MedTech firm listed on Nasdaq Stockholm’s Small Cap segment, develops noble metal coating technologies that prevent infections on medical devices and offers wound care products across orthopedics, cardiology,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026